528 related articles for article (PubMed ID: 30677788)
1. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
[TBL] [Abstract][Full Text] [Related]
3. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
4. Association between hepcidin, haemoglobin level and iron status in stage 4 chronic kidney disease patients with anaemia.
Mogadam RA; Nemati A; Amani F; Ghorbanihaghjo A; Argani H; Bashardoust B
J Pak Med Assoc; 2015 Apr; 65(4):354-7. PubMed ID: 25976565
[TBL] [Abstract][Full Text] [Related]
5. Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD).
Lee SW; Kim YH; Chung W; Park SK; Chae DW; Ahn C; Kim YS; Sung SA
Kidney Blood Press Res; 2017; 42(6):1183-1192. PubMed ID: 29227972
[TBL] [Abstract][Full Text] [Related]
6. Association of hepcidin and anemia in early chronic kidney disease.
Sonkar SK; Singh NK; Sonkar GK; Pandey S; Bhosale V; Kumar A; Usman K
Saudi J Kidney Dis Transpl; 2019; 30(2):315-324. PubMed ID: 31031367
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin.
Agarwal AK; Yee J
Adv Chronic Kidney Dis; 2019 Jul; 26(4):298-305. PubMed ID: 31477260
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease.
Malyszko J; Malyszko JS; Matuszkiewicz-Rowinska J
Expert Opin Ther Targets; 2019 May; 23(5):407-421. PubMed ID: 30907175
[TBL] [Abstract][Full Text] [Related]
9. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study.
Masajtis-Zagajewska A; Nowicki M
Ren Fail; 2018 Nov; 40(1):700-709. PubMed ID: 30741616
[TBL] [Abstract][Full Text] [Related]
10. Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.
Ueda N; Takasawa K
Curr Med Chem; 2017; 24(14):1417-1452. PubMed ID: 28302014
[TBL] [Abstract][Full Text] [Related]
11. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease.
Chand S; Ward DG; Ng ZY; Hodson J; Kirby H; Steele P; Rooplal I; Bantugon F; Iqbal T; Tselepis C; Drayson MT; Whitelegg A; Chowrimootoo M; Borrows R
J Nephrol; 2015 Feb; 28(1):81-8. PubMed ID: 24687402
[TBL] [Abstract][Full Text] [Related]
12. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
Ueda N; Takasawa K
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
[TBL] [Abstract][Full Text] [Related]
13. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.
Sun CC; Vaja V; Babitt JL; Lin HY
Am J Hematol; 2012 Apr; 87(4):392-400. PubMed ID: 22290531
[TBL] [Abstract][Full Text] [Related]
14. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.
Ganz T; Nemeth E
Semin Nephrol; 2016 Mar; 36(2):87-93. PubMed ID: 27236128
[TBL] [Abstract][Full Text] [Related]
15. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin.
Eleftheriadis T; Pissas G; Remoundou M; Filippidis G; Antoniadi G; Oustampasidou N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2014 Jan; 46(1):161-7. PubMed ID: 23860963
[TBL] [Abstract][Full Text] [Related]
16. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.
Troutt JS; Butterfield AM; Konrad RJ
J Clin Lab Anal; 2013 Nov; 27(6):504-10. PubMed ID: 24218134
[TBL] [Abstract][Full Text] [Related]
17. Hepcidin in chronic kidney disease anemia.
Santos-Silva A; Ribeiro S; Reis F; Belo L
Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Hepcidin Expression Associates with Injury Independent of Iron.
van Breda GF; Bongartz LG; Zhuang W; van Swelm RP; Pertijs J; Braam B; Cramer MJ; Swinkels DW; Doevendans PA; Verhaar MC; Masereeuw R; Joles JA; Gaillard CA
Am J Nephrol; 2016; 44(5):368-378. PubMed ID: 27771699
[TBL] [Abstract][Full Text] [Related]
20. The association of hepcidin, reticulocyte hemoglobin equivalent and anemia-related indicators on anemia in chronic kidney disease.
Gao Z; Hu Y; Gao Y; Ma X; Hu Z
Medicine (Baltimore); 2023 Apr; 102(17):e33558. PubMed ID: 37115087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
